Core Viewpoint - OpenAI has confirmed its investment in brain-computer interface (BCI) startup Merge Labs, marking its entry into a cutting-edge technology sector with a significant seed funding of $252 million (approximately 1.76 billion RMB) [2][4]. Group 1: Investment Context - The investment was anticipated in mid-2025 and is notable for its size in the BCI field, indicating OpenAI's strategic interest in the evolution of human-AI interaction [2][4]. - OpenAI's involvement is seen as a long-term bet on the development of higher bandwidth human-AI interfaces, addressing the limitations of current interaction methods [5][14]. Group 2: Merge Labs' Approach - Merge Labs, co-founded by OpenAI's CEO Sam Altman and other tech entrepreneurs, is pursuing a distinct technological path in BCI development [6][9]. - The core direction of Merge Labs includes creating a BCI system that integrates biological, device, and AI attributes, aiming for a user-friendly technology that people are willing to adopt [9][10]. Group 3: Comparison with Neuralink - Merge Labs' philosophy contrasts with Neuralink, which focuses on invasive, high-density electrode systems for clinical applications [10][12]. - Merge Labs aims to explore non-invasive or low-invasiveness methods for long-term interfaces, potentially reducing tissue damage and enhancing user acceptance [13][14]. Group 4: Industry Implications - Merge Labs is currently positioned as a research lab rather than a product-focused medical device company, aligning with OpenAI's long-term vision [14]. - The investment signals a shift in how AI companies view the integration of human neural systems into their technological narratives, suggesting a broader exploration of human-AI connections [16]. Group 5: Market Potential - Analysts have estimated the potential market size for brain-computer interfaces to reach $400 billion, highlighting the significance of this technology in future human-AI interactions [15][16].

Group 1 - The three major indices collectively rose, with the medical equipment sector showing active performance, as evidenced by the CSI All Index Medical Care Equipment and Services Index (H30178) increasing by 0.53% [1] - Notable performers within the index included Tianzhihang, which rose over 14%, Shuoshi Bio, which increased over 9%, and Sanyou Medical, which saw a rise of over 6% [1] - The Medical Equipment ETF (159873) recorded a trading volume exceeding 16 million yuan, with a subscription of 5 million units during the trading session [1] Group 2 - The Medical Equipment ETF has experienced a net inflow of funds for nine consecutive trading days, accumulating a total net inflow of 117 million yuan as of January 20 [1] - The ETF's scale has doubled over the past 20 days, reaching a latest circulating scale of 233 million yuan [1] - The ETF closely tracks the CSI All Index Medical Care Equipment and Services Index, which selects listed companies in the medical care theme to reflect the overall performance of these securities [1] Group 3 - The first human subject implanted with Neuralink's brain-machine interface, Nolan Arbo, reported that the module in his brain can be wirelessly upgraded remotely, similar to Tesla's OTA updates [2] - This marks a historic first where a human brain can be updated without surgery, allowing for performance improvements through software updates [2] - Merge Labs, a Silicon Valley startup, has raised $252 million in seed funding from investors including OpenAI, indicating strong interest in advancements in medical technology [2] Group 4 - Guotai Junan Securities noted that the scale of medical equipment bidding continues to grow, supported by ongoing implementation of equipment upgrade policies, which are expected to drive long-term procurement levels [2] - The report recommends medical equipment companies that are likely to benefit from the performance recovery driven by the implementation of these upgrade policies [2]

截至2026年1月21日 13:11，中证医药及医疗器械创新指数(931484)上涨0.03%，成分股特宝生物上涨 3.38%，甘李药业上涨2.24%，英科医疗上涨1.70%，康龙化成上涨1.23%，大博医疗上涨1.16%。医疗创 新ETF(516820)多空胶着，最新报价0.37元。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 数据显示，截至2025年12月31日，中证医药及医疗器械创新指数(931484)前十大权重股分别为药明康 德、恒瑞医药、迈瑞医疗、爱尔眼科、片仔癀、新和成、华东医药、康龙化成、艾力斯、甘李药业，前 十大权重股合计占比63.75%。 风险提示：基金有风险，投资需谨慎。基金管理人承诺以诚实信用、勤勉尽责的原则管理和运用基金资 产，但不保证本基金一定盈利，也不保证最低收益。基金管理人提醒投资人基金投资的"买者自负"原 则，在做出投资决策后，基金运营状况与基金净值变化引致的投资风险，由 ...

Group 1 - The core viewpoint of the article highlights the positive market sentiment towards the technology sector, particularly driven by new productivity areas such as brain-computer interfaces, AI applications, and commercial aerospace, with the Sci-Tech Innovation Board 100 ETF (588120) rising over 1.2% [1] - The brain-computer interface sector is stimulated by Neuralink's plan for mass production in 2026, while the commercial aerospace sector remains active as a recent market focus [1] - Continuous favorable policies are being released, including the Ministry of Finance's plan to issue ultra-long-term government bonds to support technological innovation, which is expected to guide trillions of yuan into the market [1] Group 2 - The Sci-Tech Innovation Board 100 ETF (588120) tracks the Sci-Tech 100 Index (000698), which includes 100 securities with larger market capitalization and better liquidity from the Sci-Tech Innovation Board, covering high-tech fields such as information technology and healthcare [1] - The index reflects the overall performance of representative technology innovation enterprises in the Sci-Tech Innovation Board, focusing on a growth-oriented investment style [1] - With the domestic monetary policy remaining moderately loose and foreign and long-term funds accelerating their entry into the market, there is an expectation for a spring market rally [1]

Core Viewpoint - The rehabilitation industry is viewed as a "golden track" with significant growth potential, driven by brain-computer interface (BCI) technology, which is expected to reshape the industry landscape [1] Group 1: Technological Innovation - The company focuses on three cutting-edge areas: brain-computer interfaces, rehabilitation robots, and AI medical technology, with BCI technology accelerating commercialization [2] - A comprehensive product matrix for rehabilitation robots has been established, with plans to launch 5-6 new products by 2026, including various specialized robots [2][4] - The company has initiated a brain science laboratory and developed five technical platforms to enhance its BCI technology, achieving compatibility between EEG devices and rehabilitation equipment [4] Group 2: Research and Development Investment - The company plans to maintain R&D investment at over 20% of revenue for the next 3-5 years, with more than 30% allocated to frontier technology research [5] - In the first three quarters of 2025, R&D investment reached approximately 49.09 million yuan, a year-on-year increase of 27.67%, accounting for 27.58% of quarterly revenue [5] Group 3: Market Transformation - The company has partnered with over 600 leading hospitals to establish BCI rehabilitation treatment and clinical research centers, enhancing treatment precision and effectiveness [6] - The company is transitioning from passive to active rehabilitation models, leveraging BCI technology to empower various rehabilitation products [6] Group 4: International Expansion - The company is accelerating its international market strategy, with overseas sales expected to double in 2024 compared to 2023, aiming for international revenue to account for over 30% by 2030 [7] - The company is pursuing compliance certifications such as EU CE and US FDA to facilitate international market entry and is exploring partnerships and acquisitions to enhance its global presence [7] Group 5: Ecosystem Development - The company is focused on building a comprehensive rehabilitation ecosystem, emphasizing the integration of BCI technology into rehabilitation devices, which is seen as essential for future products [8] - The trend towards lightweight, portable, and home-based rehabilitation devices is expected to drive significant growth in the home rehabilitation market [8] Group 6: Industry Integration - The company plans to strengthen its supply chain for core components and aims to execute 3-5 mergers and acquisitions between 2026 and 2030 to integrate high-growth startups [9] - The company targets to establish chain rehabilitation hospitals featuring BCI and rehabilitation robots, with a goal of achieving over 20% of service revenue by 2030 [9]

Economic Overview - In 2025, Shanghai's GDP reached 56,708.71 billion yuan, with a year-on-year growth of 5.4%, surpassing the national growth rate [1] - Shanghai's economic total ranked fifth among global cities for the first time [1] Industry Performance - The primary industry added value was 99.39 billion yuan, growing by 2.0%; the secondary industry added value was 11,650.62 billion yuan, growing by 3.5%; and the tertiary industry added value was 44,958.70 billion yuan, growing by 6.0% [1] - Industrial added value in Shanghai increased by 5.0%, with total industrial output value growing by 4.6% [1] - Notable growth in specific sectors included transportation equipment manufacturing (15.8%), electrical machinery (11.1%), automotive manufacturing (7.8%), and electronics (7.7%) [1] Leading Industries - The three leading industries in Shanghai—integrated circuits, artificial intelligence, and biomedicine—saw a manufacturing output growth of 9.6%, with integrated circuits growing by 15.1% and artificial intelligence by 13.6% [2] - Strategic emerging industries in Shanghai's industrial sector grew by 6.5%, with new energy industries increasing by 12.9% and high-end equipment industries by 11.1% [2] Service Sector Growth - The tertiary sector's added value grew by 6.0%, with information transmission, software, and IT services increasing by 15.3% and the financial sector by 9.7% [2] Consumer Market - Shanghai's total retail sales of consumer goods reached 16,600.93 billion yuan, with a year-on-year growth of 4.6%, improving by 0.3 percentage points compared to the first three quarters [2] Trade Performance - The total import and export value in Shanghai was 4.51 trillion yuan, growing by 5.6%, with exports at 2.02 trillion yuan (10.8% growth) and imports at 2.49 trillion yuan (1.8% growth) [2] - Exports of "new three samples" products reached 0.16 trillion yuan, growing by 17.4%, with electric vehicle exports increasing by 13.8% [2] Future Development Plans - The "14th Five-Year Plan" suggests that by 2035, Shanghai aims to enhance its five central functions and achieve international leading levels in key development indicators, doubling per capita GDP from 2020 [3] - The plan emphasizes agile development in quantum technology, brain-computer interfaces, controlled nuclear fusion, biomanufacturing, and sixth-generation mobile communications [3] - It also supports the establishment of an international financial asset trading platform and the development of market-oriented merger funds, venture capital funds, and foreign investment funds [3]

Group 1 - The core viewpoint emphasizes that future investments in the pharmaceutical sector should focus on the intrinsic logic of clinical value [1] - The pharmaceutical and biotechnology sectors are driven by innovation (overseas expansion, AI, new technologies), performance validation, policy dividends, and the spring market effect, with a short-term focus on innovative drugs and CXO [1] - High elasticity sub-themes include AI healthcare/AI pharmaceuticals, brain-computer interfaces, and small nucleic acid drugs, while the innovative drug industry chain and innovative medical devices are viewed positively [1] Group 2 - In the innovative medical device sector, there is optimism regarding the upgrade of high-end medical devices and high-value consumables [1] - With the global return to a rate-cutting cycle and structural policy shifts domestically, medical insurance negotiations support innovative drugs, and centralized procurement stabilizes industry profitability [1] - The valuation of the pharmaceutical sector is expected to steadily recover from the first quarter of 2025, with a clear trend of industrial quality improvement and enhanced international competitiveness [1] Group 3 - The Guotai ETF (159377) tracks the innovative pharmaceutical index (399275), which has a daily price fluctuation limit of 20% [1] - This index focuses on the innovative biopharmaceutical field, selecting listed companies involved in biotechnology, pharmaceuticals, and related medical services to reflect the overall performance of innovative biopharmaceutical securities [1]

Policy Developments - The National Healthcare Security Administration has issued a guideline for the pricing of surgical and treatment auxiliary operations, focusing on medical technology innovations such as robotic surgery and 3D printing, establishing 37 pricing items and guiding the transition from traditional to precision medicine [2] Drug and Device Approvals - Bailitianheng's drug application for iza-bren, a first-in-class EGFR×HER3 dual antibody ADC for treating recurrent or metastatic esophageal squamous cell carcinoma, has been accepted and prioritized for review by the National Medical Products Administration [4] - Heng Rui Medicine has received clinical trial approval for SHR-9839, a humanized antibody for advanced solid tumors, and HRS-4642, a KRAS G12D inhibitor [5] - Fosun Pharma's subsidiary has been approved to conduct clinical trials for HLX701 in combination with chemotherapy for advanced colorectal cancer [6] Capital Market Activities - InnoCare Pharma has entered a collaboration agreement with Shenzhen Hengtai Biotechnology for the ISM8969 project, a new NLRP3 inhibitor for CNS diseases, with a potential total payment of up to $66 million [8][9] - Zhejiang Dejin Bio completed a multi-million A round financing to advance its core product, a recombinant botulinum toxin, and for international expansion [10] Industry Developments - Ant Group's Antifor has launched a DeepSearch feature on its PC platform to assist medical professionals with literature searches and clinical diagnosis [12] - Guangzhou's political advisor has proposed a plan to develop the brain-computer interface industry, aligning with national strategies and leveraging local resources [13] Shareholder Actions - Meihua Medical announced that shareholders plan to reduce their holdings by up to 2.51% of total shares due to personal financial needs [15] - Kain Technology has voluntarily withdrawn its drug registration application for a new hepatitis B indication, which will impact its 2025 profits [16]

1月21日早盘，港股医疗板块盘初下探后持续走强。截至10:29，中证港股通医疗主题指数上涨1.4%，成 分股中，微创机器人-B涨超12%，微创医疗涨超4%，阿里健康涨超3%。 消息面上，在2026年1月举办的J.P. Morgan医疗健康大会上，全球药企密集披露前沿研发管线与大额BD 交易，为CXO行业带来明确订单预期。与此同时，AI医疗在C端的渗透正在加速，从智能问诊到慢病管 理的应用场景不断拓展，推动阿里健康、京东健康等港股互联网医疗平台价值重估。 有分析指出，当前医疗板块具备多重投资机会。CXO行业在海外订单回暖和国内产能出清的双重推动 下，景气度持续提升且估值仍具修复空间；医疗器械领域受益于国内设备更新政策支持与海外市场拓 展，脑机接口、AI影像等前沿方向催化不断；互联网医疗则在医保支付改革深化背景下，平台运营效 率持续优化，盈利增长曲线愈发清晰。 中证港股通医疗主题指数从港股通证券范围内选取50只业务涉及医疗器械、医疗商业与服务、制药与生 物科技服务等领域的股票作为指数样本，重点覆盖CXO与互联网医疗等港股特色标的。港股通医疗ETF 易方达（520850）跟踪该指数，可助力投资者精准把握医疗产业创新 ...

Core Viewpoint - The market is currently experiencing a mild adjustment phase after a period of continuous gains, with significant divergence in sector performance. The focus is shifting from event-driven themes to fundamentals, particularly in the technology growth sector, which remains the main driver of the spring market rally [1][2]. Group 1: Market Performance - The Shanghai Composite Index entered a consolidation phase after a series of gains, with a total decline in over 3,100 stocks and a trading volume shrinking to 2.8 trillion [1]. - The divergence in sector performance is notable, with differences in gains and losses exceeding 5% between leading and lagging sectors [1]. - The current market adjustment is viewed as a healthy correction that could facilitate further development of the rally, emphasizing the importance of maintaining trading volume and sector rotation [1]. Group 2: Sector Focus - The technology and materials sectors are expected to dominate in January, with a focus on themes such as commercial aerospace, brain-computer interfaces, and low-altitude economy [2]. - The rise in raw material prices, driven by technological investment trends, presents opportunities in small metals, energy metals, and new chemical materials [2]. - High-dividend traditional sectors are also suggested for left-side attention, anticipating a rebound during the annual report season in March-April [2]. Group 3: Specific Opportunities - AI hardware is projected to experience significant growth, with the peak of AI applications expected in 2026, indicating a transition from quantity to quality in AI applications [2]. - The trend of robot localization and integration into daily life is anticipated to continue, with opportunities arising in sensors, controllers, and dexterous hands as the market evolves [2]. - The semiconductor industry is expected to see continued domestic growth, with a focus on semiconductor equipment, wafer manufacturing, materials, and IC design [2]. - The demand for new energy materials is rising due to rapid growth in domestic and overseas energy storage needs, with signs of supply shortages and price increases expected to persist through 2026 [2]. - The innovative drug sector is entering a recovery phase after four years of adjustment, with positive net profit growth expected to continue into 2026 [2].